Cargando…
Synthesis and Preclinical Validation of Novel Indole Derivatives as a GPR17 Agonist for Glioblastoma Treatment
[Image: see text] The discovery of a potential ligand-targeting G protein-coupled receptor 17 (GPR17) is important for developing chemotherapeutic agents against glioblastoma multiforme (GBM). We used the integration of ligand- and structure-based cheminformatics and experimental approaches for iden...
Autores principales: | Nguyen, Phung, Doan, Phuong, Rimpilainen, Tatu, Konda Mani, Saravanan, Murugesan, Akshaya, Yli-Harja, Olli, Candeias, Nuno R., Kandhavelu, Meenakshisundaram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389915/ https://www.ncbi.nlm.nih.gov/pubmed/34304559 http://dx.doi.org/10.1021/acs.jmedchem.1c00277 |
Ejemplares similares
-
Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity
por: Doan, Phuong, et al.
Publicado: (2021) -
Synthesis and preclinical validation of novel P2Y1 receptor ligands as a potent anti-prostate cancer agent
por: Le, Hien Thi Thu, et al.
Publicado: (2019) -
Identifying the miRNA Signature Association with Aging-Related Senescence in Glioblastoma
por: Gnanavel, Mutharasu, et al.
Publicado: (2021) -
P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer
por: Le, Hien Thi Thu, et al.
Publicado: (2022) -
Battling Glioblastoma: A Novel Tyrosine Kinase Inhibitor with Multi-Dimensional Anti-Tumor Effect (Running Title: Cancer Cells Death Signalling Activation)
por: Viswanathan, Anisha, et al.
Publicado: (2019)